Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurotoxicity Syndromes | 11 | 2023 | 301 | 4.220 |
Why?
|
Brain Neoplasms | 50 | 2024 | 9031 | 3.390 |
Why?
|
Glioblastoma | 29 | 2024 | 3482 | 3.210 |
Why?
|
Central Nervous System Neoplasms | 15 | 2024 | 916 | 2.810 |
Why?
|
Cranial Irradiation | 5 | 2017 | 390 | 2.000 |
Why?
|
Glioma | 21 | 2024 | 3455 | 1.940 |
Why?
|
Antineoplastic Agents, Alkylating | 7 | 2019 | 617 | 1.930 |
Why?
|
Lymphoma | 9 | 2024 | 1901 | 1.920 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1469 | 1.860 |
Why?
|
Dacarbazine | 5 | 2016 | 559 | 1.380 |
Why?
|
Central Nervous System | 10 | 2023 | 1336 | 1.080 |
Why?
|
Antigens, CD19 | 4 | 2024 | 424 | 1.070 |
Why?
|
Radiation Injuries | 5 | 2024 | 1189 | 1.000 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 1405 | 0.880 |
Why?
|
Brain | 21 | 2024 | 27112 | 0.860 |
Why?
|
Neoplasms | 11 | 2024 | 22170 | 0.840 |
Why?
|
Stem Cells | 12 | 2010 | 3522 | 0.830 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2021 | 1374 | 0.800 |
Why?
|
Antineoplastic Agents | 18 | 2024 | 13639 | 0.780 |
Why?
|
Leukoencephalopathies | 2 | 2024 | 256 | 0.780 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.740 |
Why?
|
Radiation Injuries, Experimental | 2 | 2017 | 88 | 0.710 |
Why?
|
Nervous System Diseases | 5 | 2024 | 1666 | 0.700 |
Why?
|
Vidarabine | 1 | 2020 | 336 | 0.660 |
Why?
|
Isocitrate Dehydrogenase | 7 | 2024 | 938 | 0.630 |
Why?
|
Immunotherapy | 8 | 2023 | 4652 | 0.630 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2018 | 42 | 0.620 |
Why?
|
Methotrexate | 2 | 2023 | 1719 | 0.610 |
Why?
|
Spinal Cord Diseases | 1 | 2021 | 292 | 0.610 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2019 | 49 | 0.610 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 333 | 0.570 |
Why?
|
Central Nervous System Diseases | 1 | 2021 | 520 | 0.560 |
Why?
|
Angiogenesis Inhibitors | 7 | 2021 | 2047 | 0.550 |
Why?
|
Radiotherapy | 4 | 2019 | 1499 | 0.520 |
Why?
|
Enteric Nervous System | 2 | 2016 | 212 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2023 | 9280 | 0.500 |
Why?
|
Cognition Disorders | 5 | 2019 | 3979 | 0.500 |
Why?
|
Glutarates | 5 | 2021 | 243 | 0.490 |
Why?
|
Humans | 124 | 2024 | 761504 | 0.490 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2016 | 136 | 0.490 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2017 | 629 | 0.480 |
Why?
|
Protein Kinase Inhibitors | 5 | 2024 | 5671 | 0.460 |
Why?
|
Stem Cell Transplantation | 4 | 2016 | 1600 | 0.450 |
Why?
|
Regeneration | 2 | 2017 | 1511 | 0.450 |
Why?
|
Cell Transplantation | 1 | 2016 | 472 | 0.450 |
Why?
|
Magnetic Resonance Spectroscopy | 5 | 2024 | 3769 | 0.430 |
Why?
|
Spinal Cord Neoplasms | 1 | 2015 | 263 | 0.410 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 940 | 0.390 |
Why?
|
Muscle Weakness | 1 | 2015 | 412 | 0.390 |
Why?
|
Medulloblastoma | 1 | 2017 | 678 | 0.380 |
Why?
|
Diagnostic Imaging | 2 | 2017 | 3530 | 0.370 |
Why?
|
Back Pain | 1 | 2015 | 545 | 0.370 |
Why?
|
Neuroglia | 4 | 2015 | 956 | 0.360 |
Why?
|
Meningeal Carcinomatosis | 2 | 2021 | 63 | 0.360 |
Why?
|
Photons | 2 | 2024 | 589 | 0.350 |
Why?
|
Bone Marrow Cells | 1 | 2017 | 2416 | 0.350 |
Why?
|
Bone Marrow Transplantation | 1 | 2017 | 2693 | 0.340 |
Why?
|
Magnetic Resonance Imaging | 21 | 2024 | 36426 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11742 | 0.320 |
Why?
|
Neural Stem Cells | 1 | 2016 | 888 | 0.310 |
Why?
|
Combined Modality Therapy | 8 | 2023 | 8529 | 0.310 |
Why?
|
Cell Lineage | 4 | 2010 | 2555 | 0.300 |
Why?
|
Adult | 46 | 2024 | 221177 | 0.300 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5671 | 0.300 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 3492 | 0.290 |
Why?
|
Brain Diseases | 3 | 2018 | 1545 | 0.290 |
Why?
|
Lateral Ventricles | 2 | 2021 | 146 | 0.290 |
Why?
|
Drug Evaluation | 1 | 2008 | 641 | 0.290 |
Why?
|
Male | 54 | 2024 | 360804 | 0.280 |
Why?
|
Necrosis | 3 | 2020 | 1611 | 0.280 |
Why?
|
Lower Extremity | 1 | 2015 | 1202 | 0.280 |
Why?
|
Hydrothorax | 1 | 2006 | 18 | 0.270 |
Why?
|
Meningeal Neoplasms | 3 | 2022 | 1248 | 0.270 |
Why?
|
Mutation | 14 | 2024 | 30052 | 0.270 |
Why?
|
Bone Marrow | 1 | 2016 | 2911 | 0.270 |
Why?
|
Middle Aged | 40 | 2024 | 220895 | 0.260 |
Why?
|
Retrospective Studies | 19 | 2024 | 80636 | 0.260 |
Why?
|
Multiple Myeloma | 1 | 2023 | 5146 | 0.250 |
Why?
|
Cerebral Hemorrhage | 1 | 2017 | 2656 | 0.250 |
Why?
|
Eukaryotic Initiation Factor-2B | 1 | 2005 | 9 | 0.250 |
Why?
|
Aged | 33 | 2024 | 169289 | 0.240 |
Why?
|
T-Lymphocytes | 5 | 2023 | 10194 | 0.240 |
Why?
|
Cell Culture Techniques | 2 | 2002 | 1667 | 0.240 |
Why?
|
Neurons | 6 | 2015 | 9463 | 0.230 |
Why?
|
Female | 51 | 2024 | 392644 | 0.230 |
Why?
|
Fatal Outcome | 2 | 2020 | 1834 | 0.220 |
Why?
|
Herpesvirus 6, Human | 1 | 2004 | 96 | 0.220 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2022 | 2547 | 0.220 |
Why?
|
Radiosurgery | 3 | 2023 | 1342 | 0.210 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 553 | 0.210 |
Why?
|
Therapies, Investigational | 1 | 2023 | 111 | 0.210 |
Why?
|
B-Cell Maturation Antigen | 1 | 2023 | 149 | 0.200 |
Why?
|
Astrocytes | 3 | 2005 | 1346 | 0.200 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2021 | 638 | 0.200 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 1347 | 0.200 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 276 | 0.200 |
Why?
|
DNA Modification Methylases | 2 | 2020 | 210 | 0.200 |
Why?
|
Gangliosides | 1 | 2002 | 132 | 0.200 |
Why?
|
Loss of Heterozygosity | 1 | 2024 | 662 | 0.200 |
Why?
|
Oligodendroglia | 1 | 2006 | 538 | 0.190 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1896 | 0.190 |
Why?
|
Prognosis | 14 | 2024 | 29625 | 0.190 |
Why?
|
Cell Differentiation | 6 | 2009 | 11528 | 0.190 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2115 | 0.190 |
Why?
|
DNA Repair Enzymes | 2 | 2020 | 346 | 0.180 |
Why?
|
Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
Epilepsy, Generalized | 1 | 2023 | 178 | 0.180 |
Why?
|
Maximum Tolerated Dose | 2 | 2020 | 883 | 0.180 |
Why?
|
Quinolines | 2 | 2016 | 764 | 0.170 |
Why?
|
Neurosurgical Procedures | 2 | 2024 | 2072 | 0.170 |
Why?
|
Echo-Planar Imaging | 1 | 2024 | 663 | 0.170 |
Why?
|
Meningioma | 2 | 2022 | 1218 | 0.170 |
Why?
|
Disease Management | 3 | 2020 | 2508 | 0.170 |
Why?
|
Peritoneal Neoplasms | 1 | 2006 | 711 | 0.170 |
Why?
|
Epilepsies, Partial | 1 | 2023 | 431 | 0.160 |
Why?
|
Animals | 17 | 2024 | 168459 | 0.160 |
Why?
|
Brain Injuries | 2 | 2024 | 2053 | 0.160 |
Why?
|
Neurogenesis | 2 | 2016 | 863 | 0.160 |
Why?
|
Stuttering | 1 | 2018 | 25 | 0.160 |
Why?
|
Demyelinating Diseases | 2 | 2015 | 351 | 0.150 |
Why?
|
Signal Transduction | 2 | 2012 | 23445 | 0.150 |
Why?
|
Treatment Outcome | 13 | 2024 | 64680 | 0.150 |
Why?
|
Protons | 1 | 2023 | 1116 | 0.150 |
Why?
|
Intracranial Hemorrhages | 1 | 2003 | 822 | 0.150 |
Why?
|
Young Adult | 11 | 2024 | 59243 | 0.150 |
Why?
|
Disease Progression | 5 | 2022 | 13506 | 0.150 |
Why?
|
Neuroendocrine Tumors | 1 | 2024 | 641 | 0.150 |
Why?
|
Pyridazines | 1 | 2019 | 202 | 0.150 |
Why?
|
Radiotherapy Dosage | 2 | 2023 | 2898 | 0.140 |
Why?
|
Testicular Neoplasms | 1 | 2003 | 799 | 0.140 |
Why?
|
Head | 1 | 2023 | 924 | 0.140 |
Why?
|
Cholinesterase Inhibitors | 1 | 2019 | 242 | 0.140 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13380 | 0.140 |
Why?
|
Survival Rate | 7 | 2024 | 12725 | 0.130 |
Why?
|
Folic Acid | 1 | 2023 | 1323 | 0.130 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 495 | 0.130 |
Why?
|
Capillary Permeability | 1 | 2019 | 773 | 0.130 |
Why?
|
Lactams, Macrocyclic | 1 | 2017 | 318 | 0.130 |
Why?
|
Neurology | 1 | 2024 | 780 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 698 | 0.130 |
Why?
|
Neurodegenerative Diseases | 1 | 2005 | 1087 | 0.130 |
Why?
|
Mice | 7 | 2024 | 81525 | 0.130 |
Why?
|
Antineoplastic Protocols | 1 | 2015 | 48 | 0.130 |
Why?
|
Forecasting | 2 | 2019 | 2928 | 0.130 |
Why?
|
Pituitary Neoplasms | 1 | 2024 | 1324 | 0.130 |
Why?
|
Serotonin 5-HT4 Receptor Agonists | 1 | 2015 | 11 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 12974 | 0.120 |
Why?
|
Karnofsky Performance Status | 4 | 2019 | 166 | 0.120 |
Why?
|
Optic Nerve Neoplasms | 1 | 2015 | 45 | 0.120 |
Why?
|
Corpus Callosum | 2 | 2014 | 751 | 0.120 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2017 | 1626 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5709 | 0.120 |
Why?
|
Dexamethasone | 1 | 2022 | 1948 | 0.120 |
Why?
|
Methylphenidate | 1 | 2019 | 488 | 0.120 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 587 | 0.120 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2014 | 44 | 0.120 |
Why?
|
Imaging, Three-Dimensional | 4 | 2024 | 4063 | 0.120 |
Why?
|
Drug Delivery Systems | 1 | 2006 | 2226 | 0.120 |
Why?
|
Erythropoietin | 1 | 2019 | 719 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2825 | 0.110 |
Why?
|
Aged, 80 and over | 9 | 2024 | 58976 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7390 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1180 | 0.110 |
Why?
|
Promoter Regions, Genetic | 2 | 2024 | 5789 | 0.110 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 664 | 0.110 |
Why?
|
Valproic Acid | 1 | 2016 | 443 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 2 | 2020 | 2803 | 0.100 |
Why?
|
Gene Rearrangement | 1 | 2017 | 1125 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5315 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2016 | 18965 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14605 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2014 | 535 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3826 | 0.100 |
Why?
|
Stereotaxic Techniques | 1 | 2014 | 555 | 0.100 |
Why?
|
Child | 6 | 2023 | 80153 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1589 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5305 | 0.090 |
Why?
|
Follow-Up Studies | 8 | 2024 | 39106 | 0.090 |
Why?
|
Cell Division | 3 | 2004 | 4465 | 0.090 |
Why?
|
Colitis | 2 | 2021 | 1233 | 0.090 |
Why?
|
Laser Therapy | 1 | 2018 | 1092 | 0.090 |
Why?
|
Electroencephalography | 4 | 2023 | 6225 | 0.090 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2002 | 3612 | 0.090 |
Why?
|
Macrophages | 2 | 2017 | 5769 | 0.090 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 597 | 0.090 |
Why?
|
Prospective Studies | 10 | 2024 | 54425 | 0.090 |
Why?
|
Central Nervous System Stimulants | 1 | 2019 | 1177 | 0.090 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3877 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1551 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1784 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2321 | 0.080 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2578 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1069 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3617 | 0.080 |
Why?
|
Adenocarcinoma | 1 | 2006 | 6346 | 0.080 |
Why?
|
Genotype | 1 | 2023 | 12990 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2018 | 3712 | 0.080 |
Why?
|
Genetic Variation | 1 | 2004 | 6567 | 0.080 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 980 | 0.080 |
Why?
|
Frontal Lobe | 1 | 2015 | 1420 | 0.080 |
Why?
|
Indoles | 2 | 2014 | 1833 | 0.080 |
Why?
|
Monocytes | 1 | 2017 | 2570 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2017 | 2425 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2244 | 0.080 |
Why?
|
Cell Proliferation | 3 | 2016 | 10445 | 0.070 |
Why?
|
Bromodeoxyuridine | 2 | 2008 | 311 | 0.070 |
Why?
|
Brain Damage, Chronic | 1 | 2009 | 267 | 0.070 |
Why?
|
Nausea | 2 | 2021 | 679 | 0.070 |
Why?
|
Epilepsy | 1 | 2023 | 3290 | 0.070 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 1590 | 0.070 |
Why?
|
Echoencephalography | 1 | 2007 | 134 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2084 | 0.070 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2007 | 231 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6814 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4398 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2298 | 0.070 |
Why?
|
Adolescent | 7 | 2021 | 88319 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4853 | 0.070 |
Why?
|
Doxorubicin | 2 | 2004 | 2224 | 0.070 |
Why?
|
Cell Survival | 1 | 2016 | 5791 | 0.060 |
Why?
|
Lumbar Vertebrae | 1 | 2015 | 1879 | 0.060 |
Why?
|
Mice, Inbred CBA | 1 | 2006 | 436 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4511 | 0.060 |
Why?
|
Diffusion Tensor Imaging | 1 | 2015 | 2400 | 0.060 |
Why?
|
Child, Preschool | 2 | 2018 | 42230 | 0.060 |
Why?
|
Survival Analysis | 5 | 2021 | 10090 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8547 | 0.060 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2004 | 151 | 0.060 |
Why?
|
Amino Acid Transport System X-AG | 1 | 2004 | 39 | 0.060 |
Why?
|
Myelin Sheath | 1 | 2008 | 653 | 0.060 |
Why?
|
Rats | 4 | 2009 | 23742 | 0.060 |
Why?
|
Ifosfamide | 1 | 2003 | 232 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4876 | 0.050 |
Why?
|
Germinoma | 1 | 2003 | 132 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2004 | 411 | 0.050 |
Why?
|
Fluorouracil | 1 | 2008 | 1641 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4320 | 0.050 |
Why?
|
S Phase | 1 | 2004 | 421 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18252 | 0.050 |
Why?
|
G1 Phase | 1 | 2004 | 403 | 0.050 |
Why?
|
Neurotrophin 3 | 1 | 2002 | 61 | 0.050 |
Why?
|
Sialic Acids | 1 | 2002 | 123 | 0.050 |
Why?
|
Neural Cell Adhesion Molecule L1 | 1 | 2002 | 44 | 0.050 |
Why?
|
Carbamazepine | 1 | 2023 | 224 | 0.050 |
Why?
|
Etoposide | 1 | 2003 | 634 | 0.050 |
Why?
|
Oligodendroglioma | 1 | 2004 | 279 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2017 | 14414 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4227 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6484 | 0.050 |
Why?
|
Brain Tissue Transplantation | 1 | 2002 | 81 | 0.050 |
Why?
|
Glutamine | 1 | 2024 | 577 | 0.050 |
Why?
|
Seizures | 2 | 2023 | 2957 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2020 | 3357 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4174 | 0.050 |
Why?
|
Antigens, Differentiation | 1 | 2004 | 910 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 154 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2023 | 360 | 0.050 |
Why?
|
Glycolysis | 1 | 2024 | 835 | 0.040 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2645 | 0.040 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 22169 | 0.040 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 592 | 0.040 |
Why?
|
Carotid Stenosis | 1 | 2007 | 860 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 318 | 0.040 |
Why?
|
Risk Assessment | 2 | 2019 | 23995 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2022 | 629 | 0.040 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 2020 | 72 | 0.040 |
Why?
|
Procarbazine | 1 | 2019 | 172 | 0.040 |
Why?
|
Anticonvulsants | 2 | 2023 | 1906 | 0.040 |
Why?
|
Lomustine | 1 | 2019 | 60 | 0.040 |
Why?
|
Biological Products | 2 | 2019 | 914 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15732 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2003 | 1972 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
Tretinoin | 1 | 2002 | 519 | 0.040 |
Why?
|
Cohort Studies | 3 | 2019 | 41487 | 0.040 |
Why?
|
Telomerase | 1 | 2024 | 745 | 0.040 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 94 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2024 | 1745 | 0.040 |
Why?
|
Mood Disorders | 1 | 2006 | 1127 | 0.040 |
Why?
|
Receptor, TIE-2 | 1 | 2019 | 176 | 0.040 |
Why?
|
Cell Death | 1 | 2004 | 1678 | 0.040 |
Why?
|
Fetus | 2 | 2004 | 1863 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2019 | 350 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2371 | 0.040 |
Why?
|
Biological Evolution | 1 | 2004 | 1071 | 0.040 |
Why?
|
Glutamic Acid | 1 | 2004 | 1176 | 0.040 |
Why?
|
Dura Mater | 1 | 2020 | 290 | 0.040 |
Why?
|
Tumor Burden | 1 | 2023 | 1893 | 0.040 |
Why?
|
Cisplatin | 1 | 2003 | 1651 | 0.040 |
Why?
|
Synaptic Transmission | 1 | 2004 | 1173 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2006 | 8181 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2023 | 997 | 0.040 |
Why?
|
Vincristine | 1 | 2019 | 1036 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2003 | 1264 | 0.040 |
Why?
|
Ischemia | 1 | 2006 | 1882 | 0.030 |
Why?
|
Lactams | 1 | 2017 | 156 | 0.030 |
Why?
|
Vomiting | 1 | 2020 | 651 | 0.030 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10766 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 546 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 558 | 0.030 |
Why?
|
Hippocampus | 1 | 2008 | 3766 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15631 | 0.030 |
Why?
|
Deoxyuridine | 1 | 2015 | 34 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2645 | 0.030 |
Why?
|
Water | 1 | 2021 | 1411 | 0.030 |
Why?
|
World Health Organization | 1 | 2021 | 1322 | 0.030 |
Why?
|
Integrin alpha2 | 1 | 2015 | 39 | 0.030 |
Why?
|
Ablation Techniques | 1 | 2018 | 248 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2004 | 11076 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 39967 | 0.030 |
Why?
|
Point Mutation | 1 | 2000 | 1595 | 0.030 |
Why?
|
Thiotepa | 1 | 2014 | 66 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2023 | 12463 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2019 | 1386 | 0.030 |
Why?
|
Gene Dosage | 1 | 2019 | 1217 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1552 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1386 | 0.030 |
Why?
|
Up-Regulation | 2 | 2019 | 4124 | 0.030 |
Why?
|
Dextran Sulfate | 1 | 2015 | 256 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2015 | 185 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
Base Sequence | 1 | 2005 | 12441 | 0.030 |
Why?
|
Busulfan | 1 | 2014 | 258 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 573 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2024 | 2882 | 0.030 |
Why?
|
SOXB1 Transcription Factors | 1 | 2015 | 286 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2023 | 9000 | 0.030 |
Why?
|
Chick Embryo | 1 | 2015 | 982 | 0.030 |
Why?
|
Quality of Life | 4 | 2023 | 13367 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 17351 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2898 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2008 | 16981 | 0.030 |
Why?
|
Glucose | 1 | 2024 | 4346 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21012 | 0.030 |
Why?
|
Cytarabine | 1 | 2014 | 697 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 17635 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1001 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2018 | 962 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1376 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3123 | 0.020 |
Why?
|
Health Policy | 1 | 2024 | 2684 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 694 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 2020 | 2526 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1897 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2023 | 3548 | 0.020 |
Why?
|
NF-kappa B | 1 | 2019 | 2490 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14666 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2521 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2237 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2219 | 0.020 |
Why?
|
Autopsy | 1 | 2013 | 1008 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4915 | 0.020 |
Why?
|
Biomedical Research | 1 | 2024 | 3429 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2218 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4021 | 0.020 |
Why?
|
Models, Statistical | 1 | 2023 | 5079 | 0.020 |
Why?
|
Tetrazolium Salts | 1 | 2008 | 93 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2850 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13255 | 0.020 |
Why?
|
Pyrazoles | 1 | 2017 | 2009 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4573 | 0.020 |
Why?
|
Quinazolines | 1 | 2013 | 1371 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2008 | 613 | 0.020 |
Why?
|
Colon | 1 | 2015 | 1792 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4481 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3810 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2008 | 695 | 0.020 |
Why?
|
Auditory Pathways | 1 | 2008 | 237 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11121 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6310 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4244 | 0.020 |
Why?
|
Gene Expression | 1 | 2018 | 7581 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9177 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15266 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1978 | 0.020 |
Why?
|
Phenotype | 1 | 2002 | 16591 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 4 | 1 | 2004 | 4 | 0.010 |
Why?
|
Glutamate Plasma Membrane Transport Proteins | 1 | 2004 | 11 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7396 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 1 | 1 | 2004 | 18 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 3 | 1 | 2004 | 32 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6075 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2000 | 5777 | 0.010 |
Why?
|
Bone Morphogenetic Protein 4 | 1 | 2004 | 163 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10773 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6485 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 14031 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2004 | 89 | 0.010 |
Why?
|
Infant | 1 | 2005 | 36192 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5869 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4003 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10209 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2015 | 9539 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8124 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8830 | 0.010 |
Why?
|
Symporters | 1 | 2004 | 363 | 0.010 |
Why?
|
DNA, Antisense | 1 | 2000 | 44 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2008 | 2645 | 0.010 |
Why?
|
Thiazoles | 1 | 2008 | 1517 | 0.010 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 2000 | 54 | 0.010 |
Why?
|
Action Potentials | 1 | 2008 | 1834 | 0.010 |
Why?
|
Drug Carriers | 1 | 2004 | 706 | 0.010 |
Why?
|
Tamoxifen | 1 | 2004 | 965 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 1068 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2004 | 1699 | 0.010 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2004 | 842 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2004 | 2678 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2004 | 1189 | 0.010 |
Why?
|
Germany | 1 | 2000 | 875 | 0.010 |
Why?
|
Liposomes | 1 | 2001 | 784 | 0.010 |
Why?
|
X Chromosome | 1 | 2000 | 816 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 2819 | 0.010 |
Why?
|
Remission Induction | 1 | 2001 | 2396 | 0.010 |
Why?
|
Syndrome | 1 | 2000 | 3267 | 0.010 |
Why?
|
Reoperation | 1 | 2003 | 4303 | 0.010 |
Why?
|
Pedigree | 1 | 2000 | 4542 | 0.010 |
Why?
|
Peptides | 1 | 2004 | 4358 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 15601 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20098 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9469 | 0.000 |
Why?
|